Market Access News | pharmaphorum

News

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan

News

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (AT

News

NICE backs digital technologies for COPD rehab

More patients in England with chronic obstructive pulmonary disease (COPD) could soon be able to access rehabilitation programmes, after cost-effectiveness watchdog NICE b

News

FDA holds back MSD’s chronic cough drug again

MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.

News

FDA says no to Checkpoint’s skin cancer drug cosibelimab

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatm

News

Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers wit

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

NICE backs digital technologies for COPD rehab

FDA holds back MSD’s chronic cough drug again

FDA says no to Checkpoint’s skin cancer drug cosibelimab

Eisai files biliary tract cancer drug tasurgratinib in Japan

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks